BioWorld Asia

April 30, 2003

Diatos Licenses European Rights To Cancer Drug From Medarex

PARIS - Diatos SA and Medarex Inc. signed a licensing agreement giving Diatos exclusive European rights to develop and commercialize a potential new cancer treatment. (BioWorld International) Read More

Biotech Groups In Norway Unite, Plan To Catch Up With Neighbors

Genetic Study Of Clotting Enzyme Points To 'Fantastic' Drug Target

Curnock Cook Investing Again After Forming New €150M Fund

No Abstract Read More

PPL Gives Up Plans On Plant To Manufacture AAT Product

French Companies, Agency Unite For Effort In America

Alizyme Eyes Phase III, Alliance Following Renzapride Results

GenoWay Raises EUR3.3M To Fund Work On Animal, In Vitro Models

Merck Stops Development Of Celltech PDE-4 Inhibitor

UK Industry Gathers To Celebrate 50th Anniversary Of DNA Finding

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 15, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...